Literature DB >> 9429689

No contribution of ascorbic acid to renal calcium oxalate stones.

H Gerster1.   

Abstract

Even though a certain part of oxalate in the urine derives from metabolized ascorbic acid (AA), the intake of high doses of vitamin C does not increase the risk of calcium oxalate kidney stones due to physiological regulatory factor: gastrointestinal absorption as well as renal tubular reabsorption of AA are saturable processes, and the metabolic transformation of AA to oxalate is limited as well. Older assays for urinary oxalate favored in vitro conversion of AA to oxalate during storage and processing of the samples. Recurrent stone formers and patients with renal failure who have a defect in AA or oxalate metabolism should restrict daily vitamin C intakes to approximately 100 mg. But in the large-scale Harvard Prospective Health Professional Follow-Up Study, those groups in the highest quintile of vitamin C intake (> 1,500 mg/day) had a lower risk of kidney stones than the groups in the lowest quintiles.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9429689     DOI: 10.1159/000177954

Source DB:  PubMed          Journal:  Ann Nutr Metab        ISSN: 0250-6807            Impact factor:   3.374


  8 in total

Review 1.  Intestinal transport of an obdurate anion: oxalate.

Authors:  Marguerite Hatch; Robert W Freel
Journal:  Urol Res       Date:  2004-11-25

Review 2.  Dietary recommendations and treatment of patients with recurrent idiopathic calcium stone disease.

Authors:  W G Robertson
Journal:  Urolithiasis       Date:  2015-12-08       Impact factor: 3.436

3.  Asymptomatic kidney stones in long-term survivors of childhood acute lymphoblastic leukemia.

Authors:  S C Kaste; N A Thomas; S N Rai; K Cheon; E McCammon; R Chesney; D Jones; C-H Pui; M M Hudson
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528

Review 4.  Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach.

Authors:  E Klimant; H Wright; D Rubin; D Seely; M Markman
Journal:  Curr Oncol       Date:  2018-04-30       Impact factor: 3.677

5.  No Reported Renal Stones with Intravenous Vitamin C Administration: A Prospective Case Series Study.

Authors:  Melissa Prier; Anitra C Carr; Nicola Baillie
Journal:  Antioxidants (Basel)       Date:  2018-05-21

6.  A Case of Chronic Calcium Oxalate Nephropathy due to Short Bowel Syndrome and Cholecystectomy.

Authors:  Seiji Hashimoto; Rie Yamamoto; Tomochika Maoka; Yuichiro Fukasawa; Takao Koike; Takashi Shigematsu
Journal:  Case Rep Nephrol Dial       Date:  2018-08-10

7.  Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer.

Authors:  Christopher M Stephenson; Robert D Levin; Thomas Spector; Christopher G Lis
Journal:  Cancer Chemother Pharmacol       Date:  2013-05-14       Impact factor: 3.333

8.  Retrospective Evaluation of Clinical Experience With Intravenous Ascorbic Acid in Patients With Cancer.

Authors:  Anthony J Bazzan; George Zabrecky; Nancy Wintering; Andrew B Newberg; Daniel A Monti
Journal:  Integr Cancer Ther       Date:  2018-05-17       Impact factor: 3.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.